# PROSTATE CANCER
229 samples - 2.5 % of the cohort (P: 66 - 28.8 % | M: 163 - 71.2 %)
222 samples with TP53 hits - 96.94 % (P: 64 - 28.8 % | M: 158 - 71.2 %)